Prokinetic Agents for Gastrointestinal Motility Disorders

Introduction to Prokinetic Agents

Metoclopramide and erythromycin are the only prokinetic agents currently available in the United States for treating gastrointestinal motility disorders 1, 2, 3

The American Gastroenterological Association recommends metoclopramide as the only FDA-approved medication for gastroparesis in the United States, with a dosing regimen of 10 mg three times daily, taken 30 minutes before meals 4, 5
Treatment with metoclopramide should be limited to less than 12 weeks due to the risk of tardive dyskinesia, which carries a black box warning 6, 5

Erythromycin can be administered orally or intravenously as an off-label prokinetic agent, acting as a motilin receptor agonist, mimicking the effect of the endogenous hormone motilin 1, 2, 3
The use of erythromycin is limited by the development of tachyphylaxis, making it most effective for acute exacerbations rather than chronic management 5

Domperidone, a dopamine D2 receptor antagonist, is not FDA-approved in the United States but is available in other countries, and has the advantage of not crossing the blood-brain barrier, resulting in fewer central nervous system side effects 1, 2, 3
Tegaserod, a partial 5-HT4 receptor agonist, enhances gastric emptying but has no confirmed efficacy in reducing gastroparesis symptoms and is not approved for this indication 1, 2, 3

The American Academy of Pediatrics recommends avoiding the continuation of metoclopramide beyond 12 weeks without careful reassessment due to the cumulative risk of irreversible tardive dyskinesia 4, 5
Opioids and GLP-1 agonists should be withdrawn in patients with gastroparesis, as these medications directly impair gastrointestinal motility and worsen symptoms 4, 5
Prokinetics should not be used as first-line therapy without implementing dietary modifications first, including 5-6 small, low-fat, low-fiber meals daily 4, 5
The evidence for prokinetic efficacy is limited, with guidelines stating that there is insufficient evidence to support routine use of any prokinetic agent in infants or children with GERD 6